☰

Brendan D. Looyenga, Ph.D. - Publications

Affiliations: 
2006 University of Michigan, Ann Arbor, Ann Arbor, MI 
Area:
Molecular Biology, Cell Biology, Physiology Biology
Tree Info Grants Similar researchers PubMed Report error

24 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Rosette KA, Lander SM, VanOpstall C, Looyenga BD. Three-dimensional coculture provides an improved in vitro model for papillary renal cell carcinoma. American Journal of Physiology. Renal Physiology. 321: F33-F46. PMID 34029144 DOI: 10.1152/ajprenal.00141.2021  0.381
2020 Lodge EK, Bell JD, Roloff EM, Hamilton KE, Louters LL, Looyenga BD. Pharmacologic inhibition of N-linked glycan trimming with kifunensine disrupts GLUT1 trafficking and glucose uptake. Biochimie. PMID 32298759 DOI: 10.1016/J.Biochi.2020.04.001  0.338
2019 Rylaarsdam LE, Johnecheck GN, Looyenga BD, Louters LL. GLUT1 is associated with sphingolipid-organized, cholesterol-independent domains in L929 mouse fibroblast cells. Biochimie. PMID 30980844 DOI: 10.1016/J.Biochi.2019.04.010  0.305
2018 Lanning NJ, VanOpstall C, Goodall ML, MacKeigan JP, Looyenga BD. LRRK2 Deficiency Impairs trans-Golgi to Lysosome Trafficking and Endocytic Cargo Degradation in Human Renal Proximal Tubule Epithelial Cells. American Journal of Physiology. Renal Physiology. PMID 30089035 DOI: 10.1152/Ajprenal.00009.2018  0.333
2016 Looyenga B, VanOpstall C, Lee Z, Bell J, Lodge E, Wrobel K, Arnoys E, Louters L. Determination of GLUT1 Oligomerization Parameters using Bioluminescent Förster Resonance Energy Transfer. Scientific Reports. 6: 29130. PMID 27357903 DOI: 10.1038/Srep29130  0.311
2013 Looyenga BD, Resau J, MacKeigan JP. Cytokine receptor-like factor 1 (CRLF1) protects against 6-hydroxydopamine toxicity independent of the gp130/JAK signaling pathway. Plos One. 8: e66548. PMID 23818941 DOI: 10.1371/Journal.Pone.0066548  0.356
2012 Looyenga BD, Mackeigan JP. Characterization of differential protein tethering at the plasma membrane in response to epidermal growth factor signaling. Journal of Proteome Research. 11: 3101-11. PMID 22559174 DOI: 10.1021/Pr201077D  0.304
2012 Looyenga BD, Hutchings D, Cherni I, Kingsley C, Weiss GJ, Mackeigan JP. STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. Plos One. 7: e30820. PMID 22319590 DOI: 10.1371/Journal.Pone.0030820  0.416
2012 Looyenga BD. Abstract 168: Cytokine signaling through the JAK2/STAT3 pathway is a viable therapeutic target in non-small cell lung cancer Cancer Research. 72: 168-168. DOI: 10.1158/1538-7445.Am2012-168  0.404
2011 Ding Y, Huang D, Zhang Z, Smith J, Petillo D, Looyenga BD, Feenstra K, Mackeigan JP, Furge KA, Teh BT. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets. Cancer Research. 71: 5225-34. PMID 21642374 DOI: 10.1158/0008-5472.Can-11-0076  0.416
2011 Martin KR, Xu Y, Looyenga BD, Davis RJ, Wu CL, Tremblay ML, Xu HE, MacKeigan JP. Identification of PTPsigma as an autophagic phosphatase. Journal of Cell Science. 124: 812-9. PMID 21303930 DOI: 10.1242/Jcs.080341  0.326
2011 Looyenga BD, Furge KA, Dykema KJ, Koeman J, Swiatek PJ, Giordano TJ, West AB, Resau JH, Teh BT, MacKeigan JP. Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. Proceedings of the National Academy of Sciences of the United States of America. 108: 1439-44. PMID 21220347 DOI: 10.1073/Pnas.1012500108  0.487
2011 Looyenga BD, Furge KA, Dykema KJ, Koeman J, Swiatek PJ, Giordano TJ, West AB, Resau JH, Teh BT, MacKeigan JP. Abstract 4036: Chromosomal amplification of LRRK2 is required for oncogenic MET signaling in papillary renal and thyroid carcinomas Cancer Research. 71: 4036-4036. DOI: 10.1158/1538-7445.Am2011-4036  0.472
2011 Martin KR, Xu Y, Looyenga BD, Davis RJ, Wu C, Tremblay ML, Xu HE, Mackeigan JP. Abstract 3836: Identification of PTPsigma as an autophagic phosphatase Cancer Research. 71: 3836-3836. DOI: 10.1158/1538-7445.Am2011-3836  0.317
2010 Looyenga BD, Wiater E, Vale W, Hammer GD. Inhibin-A antagonizes TGFbeta2 signaling by down-regulating cell surface expression of the TGFbeta coreceptor betaglycan. Molecular Endocrinology (Baltimore, Md.). 24: 608-20. PMID 20160125 DOI: 10.1210/Me.2008-0374  0.596
2007 Looyenga BD, Hammer GD. Genetic removal of Smad3 from inhibin-null mice attenuates tumor progression by uncoupling extracellular mitogenic signals from the cell cycle machinery. Molecular Endocrinology (Baltimore, Md.). 21: 2440-57. PMID 17652186 DOI: 10.1210/Me.2006-0402  0.646
2006 Looyenga BD, Hammer GD. Origin and identity of adrenocortical tumors in inhibin knockout mice: implications for cellular plasticity in the adrenal cortex. Molecular Endocrinology (Baltimore, Md.). 20: 2848-63. PMID 16873442 DOI: 10.1210/Me.2006-0182  0.655
2006 Johnsen IK, Slawik M, Shapiro I, Hartmann MF, Wudy SA, Looyenga BD, Hammer GD, Reincke M, Beuschlein F. Gonadectomy in mice of the inbred strain CE/J induces proliferation of sub-capsular adrenal cells expressing gonadal marker genes. The Journal of Endocrinology. 190: 47-57. PMID 16837610 DOI: 10.1677/Joe.1.06750  0.654
2005 Robertson SA, Schoumans J, Looyenga BD, Yuhas JA, Zylstra CR, Koeman JM, Swiatek PJ, Teh BT, Williams BO. Spectral karyotyping of sarcomas and fibroblasts derived from Ink4a/Arf-deficient mice reveals chromosomal instability in vitro. International Journal of Oncology. 26: 629-34. PMID 15703817 DOI: 10.3892/Ijo.26.3.629  0.375
2004 Looyenga B, Beuschlein F, Nilson J, Hammer GD. Mechanistic roles of inhibin as a tumor suppressor in the adrenal cortex Endocrine Research. 30: 585-586. PMID 15666795 DOI: 10.1081/Erc-200043745  0.606
2004 Beuschlein F, Looyenga BD, Reincke M, Hammer GD. Role of the inhibin/activin system and luteinizing hormone in adrenocortical tumorigenesis. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et MéTabolisme. 36: 392-6. PMID 15241730 DOI: 10.1055/S-2004-814584  0.654
2004 Beuschlein F, Looyenga B, Hammer G. The Role of Inhibin and Activin in Adrenal Tumorigenesis Hormone and Metabolic Research. 36. DOI: 10.1055/S-2004-830831  0.549
2003 Beuschlein F, Looyenga BD, Bleasdale SE, Mutch C, Bavers DL, Parlow AF, Nilson JH, Hammer GD. Activin induces x-zone apoptosis that inhibits luteinizing hormone-dependent adrenocortical tumor formation in inhibin-deficient mice. Molecular and Cellular Biology. 23: 3951-64. PMID 12748296 DOI: 10.1128/Mcb.23.11.3951-3964.2003  0.637
2003 Beuschlein F, Looyenga BD, Reincke M, Giordano TJ, Hammer GD. Clinical Impact of Recent Advances in the Biology of Adrenocortical Cancer The Endocrinologist. 13: 470-478. DOI: 10.1097/01.Ten.0000100240.50691.5A  0.613
Show low-probability matches.